Overview
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent document
- Diagnosed with soft tissue sarcoma
- Undergoing resection of lung lesion as part of standard care
Exclusion Criteria:
1\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
